Biotinylated Delta Variant Spike RBD SARS-CoV-2

<strong>Biotinylated Delta Variant Spike RBD SARS-CoV-2  </strong>_x000D_ <strong>Catalog number:</strong> B2010481_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 25 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> 27 kDa_x000D_ <strong>Supplied as:</strong> Buffered Solution_x000D_ <strong>Appearance:</strong> Solution_x000D_ <strong>Applications:</strong> highly pure (&gt; 95%) biotinylated SARS-CoV-2 RBD of the Delta Variant. This protein was expressed in HEK293, biotinylated in vitro and tested for its ability to bind the human cellular receptor ACE2._x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong> Biotin RBD, Biotin Delta RBD_x000D_ <strong>Grade:</strong> Biotechnology grade. All solid components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <a href="https://moleculardepot.com/wp-content/uploads/2022/03/MKT-010-SARS-CoV-2-Brochure-Rev-A.pdf"><strong>Download SARS-CoV-2 Brochure</strong></a>_x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Bertoglio F, Fühner V, Ruschig M, Heine PA, Abassi L, Klünemann T, Rand U,_x000D_ Meier D, Langreder N, Steinke S, Ballmann R, Schneider KT, Roth KDR, Kuhn P,_x000D_ Riese P, Schäckermann D, Korn J, Koch A, Chaudhry MZ, Eschke K, Kim Y, Zock-_x000D_ Emmenthal S, Becker M, Scholz M, Moreira GMSG, Wenzel EV, Russo G, Garritsen_x000D_ HSP, Casu S, Gerstner A, Roth G, Adler J, Trimpert J, Hermann A, Schirrmann T,_x000D_ Dübel S, Frenzel A, Van den Heuvel J, Čičin-Šain L, Schubert M, Hust M. A SARS-_x000D_ CoV-2 neutralizing antibody selected from COVID-19 patients binds to the_x000D_ ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Rep. 2021_x000D_ Jul 27;36(4):109433._x000D_ _x000D_ 2: Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes_x000D_ BF, Sanders KO, Gnanakaran S, Hengartner N, Pajon R, Smith G, Glenn GM, Korber_x000D_ B, Montefiori DC. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing_x000D_ antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 2021 Apr_x000D_ 14;29(4):529-539.e3._x000D_ _x000D_ 3: Ou J, Zhou Z, Dai R, Zhang J, Zhao S, Wu X, Lan W, Ren Y, Cui L, Lan Q, Lu L,_x000D_ Seto D, Chodosh J, Wu J, Zhang G, Zhang Q. V367F Mutation in SARS-CoV-2 Spike_x000D_ RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity_x000D_ through Increased Human ACE2 Receptor Binding Affinity. J Virol. 2021 Jul_x000D_ 26;95(16):e0061721._x000D_ _x000D_ 4: Pymm P, Adair A, Chan LJ, Cooney JP, Mordant FL, Allison CC, Lopez E,_x000D_ Haycroft ER, O'Neill MT, Tan LL, Dietrich MH, Drew D, Doerflinger M, Dengler MA,_x000D_ Scott NE, Wheatley AK, Gherardin NA, Venugopal H, Cromer D, Davenport MP,_x000D_ Pickering R, Godfrey DI, Purcell DFJ, Kent SJ, Chung AW, Subbarao K, Pellegrini_x000D_ M, Glukhova A, Tham WH. Nanobody cocktails potently neutralize SARS-CoV-2 D614G_x000D_ N501Y variant and protect mice. Proc Natl Acad Sci U S A. 2021 May_x000D_ 11;118(19):e2101918118._x000D_ _x000D_ 5: Gobeil SM, Janowska K, McDowell S, Mansouri K, Parks R, Stalls V, Kopp MF,_x000D_ Manne K, Saunders K, Edwards RJ, Haynes BF, Henderson RC, Acharya P. Effect of_x000D_ natural mutations of SARS-CoV-2 on spike structure, conformation and_x000D_ antigenicity. bioRxiv [Preprint]. 2021 Mar 15:2021.03.11.435037._x000D_ _x000D_ 6: Khan A, Wei DQ, Kousar K, Abubaker J, Ahmad S, Ali J, Al-Mulla F, Ali SS,_x000D_ Nizam-Uddin N, Mohammad Sayaf A, Mohammad A. Preliminary Structural Data_x000D_ Revealed That the SARS-CoV-2 B.1.617 Variant's RBD Binds to ACE2 Receptor_x000D_ Stronger Than the Wild Type to Enhance the Infectivity. Chembiochem. 2021 Aug_x000D_ 17;22(16):2641-2649._x000D_ _x000D_ 7: Tsai MS, Yang YH, Lin YS, Chang GH, Hsu CM, Yeh RA, Shu LH, Cheng YC, Liu HT,_x000D_ Wu YH, Wu YH, Shen RC, Wu CY. GB-2 blocking the interaction between ACE2 and_x000D_ wild type and mutation of spike protein of SARS-CoV-2. Biomed Pharmacother. 2021_x000D_ Aug 5;142:112011._x000D_ _x000D_ 8: Gobeil SM, Janowska K, McDowell S, Mansouri K, Parks R, Stalls V, Kopp MF,_x000D_ Manne K, Li D, Wiehe K, Saunders KO, Edwards RJ, Korber B, Haynes BF, Henderson_x000D_ R, Acharya P. Effect of natural mutations of SARS-CoV-2 on spike structure,_x000D_ conformation, and antigenicity. Science. 2021 Aug 6;373(6555):eabi6226._x000D_ _x000D_ 9: Deshpande A, Harris BD, Martinez-Sobrido L, Kobie JJ, Walter MR. Epitope_x000D_ Classification and RBD Binding Properties of Neutralizing Antibodies Against_x000D_ SARS-CoV-2 Variants of Concern. Front Immunol. 2021 Jun 4;12:691715._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/34210893/">10: McCallum M, Bassi J, De Marco A, Chen A, Walls AC, Di Iulio J, Tortorici MA,_x000D_ Navarro MJ, Silacci-Fregni C, Saliba C, Sprouse KR, Agostini M, Pinto D, Culap_x000D_ K, Bianchi S, Jaconi S, Cameroni E, Bowen JE, Tilles SW, Pizzuto MS, Guastalla_x000D_ SB, Bona G, Pellanda AF, Garzoni C, Van Voorhis WC, Rosen LE, Snell G, Telenti_x000D_ A, Virgin HW, Piccoli L, Corti D, Veesler D. SARS-CoV-2 immune evasion by the_x000D_ B.1.427/B.1.429 variant of concern. Science. 2021 Aug 6;373(6555):648-654. </a>_x000D_ _x000D_ <strong>Products Related to Delta Variant SARS-CoV-2 Spike RBD Biotinylated </strong> <a href="https://moleculardepot.com/product-category/SARS-CoV-2/">: SARS-CoV-2</a>